"Samson Clinical is setting new milestones in the rediscovery of Loniten by developing low dose oral minoxidil."
- Professor Rodney Sinclair - Founder & key opinion Leader
.png)
Samson Clinical
SAMSON CLINICAL
Have any questions?
Email us at samson@samsonclinical.com
© 2025 by Ceteris Creative.
What is pattern hair loss?
Sublingual minoxidil (SLM) has been investigated as a treatment for male pattern hair loss, female pattern hair loss, telogen effluvium, alopecia areata, cicatricial alopecia, congenital hair growth disorders and chemotherapy-induced hair loss.
SLM promotes anagen to telogen transition, encouraging empty follicles to resume hair growth. It prolongs anagen duration, thereby reducing hair shedding and increasing fibre diameter to reverse balding and reduce hair breakage.
Hair follicle response to minoxidil is dose-dependant. Minoxidil lotion achieves a dose sufficient to grow hair in about 30% of users. For the remainder, the maximum dose is below the threshold required to produce hair growth. Low minoxidil solubility and saturation absorption kinetics prevent minoxidil lotion achieving a therapeutic dose in almost 70% of the populations. Low solubility contributes to powdering on the hair and poor user experience. Only about 2% of the minoxidil lotion applied to the scalp reaches the hair bulb.
Minoxidil tablets are FDA-approved to treat hypertension and are used in children over the age of 14. They are used to treat eclampsia in pregnancy. The approved dose range is between 10 and 100 mg daily. A daily dose above 5 mg is required to have any haemodynamic effect.
Low dose sublingual minoxidil targets the 'sweet spot', above the maximum dose achieved by Minoxidil Lotion and below the minimum dose required to affect blood pressure.
